Strota/ Newsroom/ 2026-09-28

TORNTPHARM (Torrent Pharmaceuticals Ltd.): Acquisition / M&A

Strota Newsroom · session of 2026-09-28 · 28 Sep 12:03 · TORNTPHARM stock page →

Torrent Pharmaceuticals Limited has informed the Exchange about Acquisition - Disclosure pursuant to Regulation 30 read… Historically, acquisition / m&a events have moved TORNTPHARM-type stocks in the bullish direction 48.9% of the next sessions (n=141).

Torrent Pharmaceuticals Ltd. informed the exchange on 28 Sep 12:03 about an acquisition under Regulation 30 of the Listing Regulations. The pack classifies the event as Acquisition / M&A with a bullish bias. The exchange headline is a disclosure notice rather than a full deal sheet in the pack, so the confirmed fact is that an acquisition filing was made, not a complete set of deal economics.

For acquisition-type events, the pack's reaction sample of n 141 shows a win_rate of 48.9 percent and net_edge_pct of 0.213 — essentially a coin-flip base rate with a thin average edge, not a directional forecast. On the cash tape, the stock's last was 4865.0 against a previous close of 4988.5, a change_pct of -2.48, while the Nifty was down 1.56 percent on the as_of date.

Technicals as of last_date 2026-09-25 showed the stock above both the 50-day and 200-day averages, 4.98 percent below the 52-week high of 5250.0 and 43.32 percent above the 52-week low of 3480.6. RSI14 was 54.2 and relative volume 1.25. Valuation fields list mcap_cr 186532.0, pe 78.64, pb 19.79, eps 62.36 and div_yield_pct 0.77. Fresh headlines in the pack are mostly older chart and shareholding items rather than deal detail.

What the pack establishes is an M&A disclosure on 28 Sep 12:03, a soft same-day cash print of -2.48 percent to 4865.0, and a near-neutral historical acquisition base rate on n 141. What it does not establish is the commercial terms of the acquisition or any claim that the filing must re-rate the stock.

The catalyst

Torrent Pharmaceuticals Limited has informed the Exchange about Acquisition - Disclosure pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ) (filing · NSE)

What the data shows after this event

Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.

TORNTPHARM right now

trading -2.48% on the day; P/E 78.64; RSI 54.2. Full TORNTPHARM analysis →

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.